# Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

> **NCT00003509** · PHASE2 · TERMINATED · sponsor: **Burzynski Research Institute** · enrollment: 13 (actual)

## Conditions studied

- Stage IV Melanoma

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003509
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-03-27
- **Primary completion:** 2005-02-14
- **Final completion:** 2005-02-14
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003509, "Antineoplaston Therapy in Treating Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00003509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*